StoreGene is focused on the development of genetic testing as part of chronic disease risk assessment. We perform genetic risk profiling for cardiovascular disease, combining traditional risk factors with genetic variants to provide a comprehensive risk profile.

Cardiovascular disease is the greatest cause of death in the developed world. Research is revealing more and more genetic factors that influence CVD, presenting greater opportunities for us to understand risk, and to estimate risk for an individual.

We collect genetic information using a non-invasive saliva sample, and combine this genetic risk information with key clinical risk factor information to calculate an individual's overall 10-year risk of CVD.

Our CVD risk reports clearly present cardiovascular risk, showing how genetic and conventional factors contribute towards the individual's overall 10-year risk score. Risk reports are sent to the clinician for discussion with the patient.

We integrate genotyping technology with conventional risk analysis to provide greater predictive accuracy of an individual's risk of chronic disease. Our genetic cardiovascular profiling service is used by national and international healthcare providers and in the private health industry. We also provide genetic testing for the monogenic genetic disease Familial Hypercholesterolaemia, a genetic disease causing raised cholesterol and increased risk of cardiovascular disease. Improvements in scientific knowledge and genotyping technologies are allowing us to expand into other diseases, increasing accuracy of risk estimation and allowing greater management of individual health.

It is important that clinicians have access to the most accurate risk information about a patient so that they can help the patient to make better-informed decisions about managing their future health.


Professor Steve Humphries, BHF Chair of Cardiovascular Genetics

UCL's StoreGene initiative provides genetic risk profiling for people at risk of CVD through a non-invasive cheek swab ... This suggests genetic testing could significantly impact on risk profiling within the next decade.


Catherine Love Soper, Pensions and Social Insurance Specialist